Particle.news

Download on the App Store

Anthem Biosciences IPO Hits Full Subscription on Day Two with Grey Market Premium Pointing to 20% Gains

Investor demand accelerated from 0.73× on Day One to 1.63× by Day Two, setting the stage for allotment on July 17 ahead of a July 21 listing

Image
Should You Invest In Anthem Biosciences IPO? Top Management Answers Key Investor Questions

Overview

  • As of midday Day 2, the IPO drew bids for 1.63× its 5.96 crore-share offer, led by a 4.34× subscription from NIIs and 1.2× from retail investors, while QIBs covered 0.39×
  • Unofficial grey market quotes place the stock at a ₹120–123 premium over the ₹570 upper band, suggesting a debut near ₹690 and listing gains above 20%
  • The entirely offer-for-sale issue follows an anchor allocation of ₹1,016 crore to 60 institutions at ₹570 a share, with participants including ADIA and the Government Pension Fund Global
  • Allotment is scheduled for July 17, subject to regulatory sign-offs, and shares are slated to list on the BSE and NSE on July 21
  • Anthem posted 30% revenue growth to ₹1,844 crore and a 23% PAT rise in FY25, and plans to commission a new cGMP facility in Karnataka in H1 FY26